

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

1. (Currently Amended) A powdered pharmaceutical composition for treating ~~asthma bronchiale in mammals~~, comprising:

formulated separately or together,

an efficacious amount of (i) loteprednol or loteprednol etabonate; and (ii) at least one β_2 adrenoreceptor agonist selected from the group consisting of salbutamol, reproterol, salmeterol, formoterol, and pharmaceutically tolerable salts there of,

for simultaneous, sequential, or separate administration by inhalation ~~in the treatment of asthma bronchiale in mammals~~, wherein the pharmaceutical composition is formulated in a powdered form.

2. (Previously Presented) The powdered pharmaceutical composition according to claim 1, comprising:

(i) loteprednol or loteprednol etabonate; and

(ii) formoterol.

3. (Previously Presented) The powdered pharmaceutical composition according to claim 1, comprising:

- (i) loteprednol or loteprednol etabonate; and
- (ii) salmeterol.

4. (Previously Presented) The powdered pharmaceutical composition according to claim 1, comprising:

- (i) loteprednol or loteprednol etabonate; and
- (ii) reproterol.

5. (Canceled).

6. (Canceled).

7. (Previously Presented) A method for the treatment of asthma bronchiale in a patient, the method comprising:

administering to the patient an efficacious amount of (i) loteprednol or loteprednol etabonate and (ii) at least one β_2 adrenoceptor agonist selected from the group consisting of salbutamol, reproterol, salmeterol, formoterol, and pharmaceutically tolerable salts there of,

wherein a pharmaceutically acceptable excipient or a vehicle is added if suitable for simultaneous, sequential or separate administration.

8. (Previously Presented) A process for the preparation of a pharmaceutical composition for the treatment of asthma bronchiale, the process comprising:

combining (i) an effective amount of the active compound loteprednol or loteprednol etabonate and (ii) an effective amount of at least one β_2 adrenoceptor agonist selected from the group consisting of salbutamol, reproterol, salmeterol, formoterol, and pharmaceutically tolerable salts there of,

wherein the loteprednol or loteprednol etabonate and one or more β_2 adrenoceptor agonists are mixed individually or together,

wherein a pharmaceutically acceptable excipient or a vehicle is added if suitable, and

wherein the composition thus obtained is converted into a powdered form suitable for inhalations.